Market closed

CRISPR/$CRSP

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About CRISPR

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Ticker

$CRSP

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Zug, Switzerland

Employees

407

Website

www.crisprtx.com

CRISPR Metrics

BasicAdvanced

$3.3B

-

-$2.90

1.66 -

Price and volume

Market cap

$3.3B

Beta

1.66

52-week high

$91.10

52-week low

$36.52

Average daily volume

1.8M

Financial strength

Current ratio

21.644

Quick ratio

21.553

Long term debt to equity

10.861

Total debt to equity

11.731

Management effectiveness

Return on assets (TTM)

-9.57%

Return on equity (TTM)

-13.07%

Valuation

Price to revenue (TTM)

15.881

Price to book

1.71

Price to tangible book (TTM)

1.71

Price to free cash flow (TTM)

-16.847

Growth

Revenue change (TTM)

19.31%

Earnings per share change (TTM)

-35.36%

3-year revenue growth (CAGR)

-39.20%

3-year earnings per share growth (CAGR)

-18.04%

What the Analysts think about CRISPR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for CRISPR stock.

CRISPR Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

CRISPR Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

CRISPR News

AllArticlesVideos

CRISPR Therapeutics AG (CRSP) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Seeking Alpha·7 hours ago

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·7 days ago

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

MarketBeat·1 week ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CRSP

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for CRISPR stock?

CRISPR (CRSP) has a market cap of $3.3B as of January 15, 2025.

What is the P/E ratio for CRISPR stock?

The price to earnings (P/E) ratio for CRISPR (CRSP) stock is 0 as of January 15, 2025.

Does CRISPR stock pay dividends?

No, CRISPR (CRSP) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next CRISPR dividend payment date?

CRISPR (CRSP) stock does not pay dividends to its shareholders.

What is the beta indicator for CRISPR?

CRISPR (CRSP) has a beta rating of 1.66. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.